WILSON TROY EDWARD — SEC Form 4 filings
SEC reporting owner CIK 1589597. 22 Form 4 filings on record with FilingPulse; latest filed 2026-09-16.
Transaction summary — filings shown
Covers all 22 filings on record, filed 2024-01-26 to 2026-09-16. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 5 legs across 4 filings — 300,000 shares, $3,064,346 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 15 legs across 8 filings — 305,821 shares, $8,171,701 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 26.
- Largest priced transaction: sale of 84,107 shares @ $20.23 ($1,701,485) in Kura Oncology, Inc., filed 2024-01-26.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Avidity Biosciences, Inc. (RNAM) | Director | 5 | — | 8 legs · 124,554 sh · $5,752,430 | 14 |
| Kura Oncology, Inc. (KURA) | President and CEO, Director | 10 | 5 legs · 300,000 sh · $3,064,346 | 3 legs · 127,667 sh · $2,169,401 | 8 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | Director | 6 | — | 4 legs · 53,600 sh · $249,870 | 3 |
| Atrium Therapeutics, Inc. (RNA) | Director | 1 | — | — | 1 |
Form 4 filings — WILSON TROY EDWARD
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-16 | 4 | PUMA BIOTECHNOLOGY, INC. (PBYI) | Sale (S): 5,000 @ $9.10 | EDGAR |
| 2026-08-24 | 4 | Kura Oncology, Inc. (KURA) | Purchase (P): 100,000 @ $12.39 | EDGAR |
| 2026-08-17 | 4 | Kura Oncology, Inc. (KURA) | Purchase (P): 100,000 @ $11.12 | EDGAR |
| 2026-06-15 | 4 | PUMA BIOTECHNOLOGY, INC. (PBYI) | Grant/award (A): 27,000 @ $0 · Sale (S): 10,800 @ $7.20 | EDGAR |
| 2026-03-25 | 4 | Kura Oncology, Inc. (KURA) | Option exercise (M): 6,103 @ $6.15 · Option exercise (M): 6,103 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Atrium Therapeutics, Inc. (RNA) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-02-27 | 4 | Avidity Biosciences, Inc. (RNAM) | Disposition to issuer (D): 65,091 · Disposition to issuer (D): 13,711 · Disposition to issuer (D): 10,034 (derivative) · Disposition to issuer (D): 13,489 (derivative) · Disposition to issuer (D): 15,000 (derivative) | EDGAR |
| 2026-01-06 | 4 | Kura Oncology, Inc. (KURA) | Grant/award (A): 1,120,000 (derivative) @ $0 | EDGAR |
| 2025-11-14 | 4 | Kura Oncology, Inc. (KURA) | Grant/award (A): 182,500 @ $0 | EDGAR |
| 2025-09-29 | 4 | Kura Oncology, Inc. (KURA) | Grant/award (A): 182,500 @ $0 · Sale (S): 36,615 @ $8.94 | EDGAR |
| 2025-09-09 | 4 | Kura Oncology, Inc. (KURA) | Purchase (P): 50,000 @ $8.20 | EDGAR |
| 2025-09-09 | 4 | Avidity Biosciences, Inc. (RNA) | Option exercise (M): 14,500 @ $12.48 · Sale (S): 14,500 @ $50 · Sale (S): 15,000 @ $50 · Option exercise (M): 14,500 (derivative) @ $0 | EDGAR |
| 2025-08-14 | 4 | Kura Oncology, Inc. (KURA) | Purchase (P): 36,506 @ $5.85 · Purchase (P): 13,494 @ $6.64 | EDGAR |
| 2025-08-08 | 4 | Avidity Biosciences, Inc. (RNA) | Option exercise (M): 22,000 @ $12.03 · Sale (S): 22,000 @ $45 · Option exercise (M): 7,500 @ $12.48 · Sale (S): 7,500 @ $45 · Sale (S): 15,000 @ $45 · Sale (S): 15,000 @ $45 · +4 more | EDGAR |
| 2025-06-17 | 4 | PUMA BIOTECHNOLOGY, INC. (PBYI) | Sale (S): 10,800 @ $3.40 | EDGAR |
| 2025-06-13 | 4 | PUMA BIOTECHNOLOGY, INC. (PBYI) | Grant/award (A): 27,000 @ $0 | EDGAR |
| 2025-06-12 | 4 | Avidity Biosciences, Inc. (RNA) | Grant/award (A): 6,692 @ $0 · Grant/award (A): 10,034 (derivative) @ $0 | EDGAR |
| 2025-01-06 | 4 | Kura Oncology, Inc. (KURA) | Grant/award (A): 625,000 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | PUMA BIOTECHNOLOGY, INC. (PBYI) | Grant/award (A): 27,000 @ $0 | EDGAR |
| 2024-06-17 | 4 | PUMA BIOTECHNOLOGY, INC. (PBYI) | Sale (S): 27,000 @ $3.33 | EDGAR |
| 2024-06-14 | 4 | Avidity Biosciences, Inc. (RNA) | Grant/award (A): 13,489 (derivative) @ $0 | EDGAR |
| 2024-01-26 | 4 | Kura Oncology, Inc. (KURA) | Option exercise (M): 6,945 @ $4.80 · Sale (S): 6,945 @ $20.23 · Option exercise (M): 84,107 @ $6.15 · Sale (S): 84,107 @ $20.23 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1589597 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →